Zevra Therapeutics, Inc.
NASDAQ:ZVRABiotechnology
+$0.31 today
- Market cap
- $552.20M
- Beta
- 0.89
- P/E (TTM)
- 6.1
- EPS (TTM)
- $2.13
Volume 0.62M
Average 1.43M
ZVRA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Zevra Therapeutics, Inc.NASDAQ: ZVRA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $368K fell 77.7% year over year, behind the -57.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at +62.5% a year.
Context
- Depreciation & amortization amounted to 3.8% of revenue in FY2025, down 23.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -77.7% toward the trailing-twelve-month pace of -57.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.05M USD
- Year-over-year change
- -36.5%
- 4-year CAGR
- +99.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.05M | -36.5% |
| FY2024 | 2024-12-31 | 6.39M | +535.1% |
| FY2023 | 2023-12-31 | 1.01M | +6.6% |
| FY2022 | 2022-12-31 | 944K | +267.3% |
| FY2021 | 2021-12-31 | 257K | — |
Depreciation & Amortization vs competitors
How ZVRA compares with its peers on the latest reported figures
- ZVRA's LTM Mar 2026 depreciation & amortization of $2.77M is the 5th highest of the 11 companies compared; the peer median is $1.46M.
- Its year-over-year change of -57.2% is the 10th highest of 11, against a peer median of -2.3%.
- Depreciation & amortization amounts to 2.3% of revenue for ZVRA, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $539.67M | -21.3% | +3.4% | 11.4% | |
| LTM Jun 2026 | $101.71M | +26.1% | +2.3% | 12.2% | |
| LTM Sep 2026 | $80.71M | +167.6% | -29.6% | 4.6% | |
| LTM Sep 2026 | $39.6M | +33.3% | +24.5% | 1.1% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Sep 2026 | $2.32M | -9.6% | +21.9% | — | |
| LTM Mar 2026 | $605K | +5.0% | +24.6% | — | |
| LTM Mar 2026 | $574K | -20.3% | +0.2% | — | |
| LTM Mar 2026 | $350K | +12.5% | +92.4% | — | |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| Peer median (excluding ZVRA) | $1.46M | -2.3% | +2.9% | 8.0% | |
Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.65M | 10.16M | 27.46M | 23.61M | 106.47M |
| Cost of Revenue | 2.06M | 222K | 2.95M | 7.42M | 16.48M |
| Gross Profit | 26.59M | 9.94M | 24.52M | 16.2M | 89.99M |
| Gross Margin | 92.8% | 97.8% | 89.3% | 68.6% | 84.5% |
| Research & Development | 10.16M | 19.8M | 39.81M | 42.1M | 12.74M |
| Selling, General & Admin | 8.7M | 15.04M | 35.09M | 54.87M | 77.62M |
| Operating Expenses | 18.86M | 52.5M | 74.12M | 103.2M | 94.22M |
| Depreciation & Amortization | 257K | 944K | 1.01M | 6.39M | 4.05M |
| EBITDA | (7.89M) | (25.53M) | (43.54M) | (76.4M) | 98.71M |
| EBITDA Margin | -27.5% | -251.2% | -158.6% | -323.6% | 92.7% |
| Operating Income | 7.73M | (42.57M) | (49.6M) | (87M) | (4.23M) |
| Operating Margin | 27.0% | -418.9% | -180.6% | -368.5% | -4.0% |
| Interest Income | 261K | 1.51M | 4.54M | 2.18M | 6.95M |
| Interest Expense | 376K | 335K | 1.5M | 7.35M | 7.98M |
| Other Income / Expenses | (16.25M) | 15.76M | 3.56M | (3.14M) | 90.91M |
| Income Before Tax | (8.52M) | (26.81M) | (46.05M) | (90.14M) | 86.68M |
| Pre-Tax Margin | -29.7% | -263.8% | -167.7% | -381.8% | 81.4% |
| Income Tax Expense | 34K | (33K) | 0 | 15.37M | 3.45M |
| Net Income | (8.56M) | (26.77M) | (46.05M) | (105.51M) | 83.23M |
| Net Margin | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% |
| EPS (Basic) | (2.11) | (0.78) | (1.30) | (2.28) | 1.40 |
| EPS (Diluted) | (2.11) | (0.78) | (1.30) | (2.28) | 1.35 |
| Weighted Avg Shares | 29.77M | 34.49M | 35.45M | 46.25M | 55.31M |
| Weighted Avg Shares (Diluted) | 29.77M | 34.49M | 35.45M | 46.25M | 57.26M |
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
Intrinsic Alpha fair value
Locked
Current Price
$9.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.